



Proposes new approach for generating new chemical compounds using Recurrent Neural Networks



Higher costs, longer timelines, and lower success rates





Research productivity in pharmaceutical recent decades



industry decreased in

Rise of de novo drug

Methods

Multiobjective de Novo Drug **Design with Recurrent Neural Networks and Nondominated**

7 Molecules are represented using the SMILES string notation

Optimizing for specific chemical

properties is hard

Acetylsalicylic Acid (Aspirin) CC(=0)0c1ccccc1C(=0)0

The network used composed of three stacked LSTM lavers. each of size 1024. regularized with a 0.2 dropout ratio.


21 million trainable parameters. Sequence length = 75 time steps




Epinephrine CNC[C@H](0)c1ccc(0)c(0)c1

Generates molecules and then selects the best ones based on nondominated sorting then train with the newly

<u>Introduction</u>



10 This process simulates the traditional design-synthesis-test cycle far more rapidly.



Sorting Results

19 Further

exploration of ML in drua

discovery offers

enormous

potential to

reduce the cost and time needed

for the

development of

drugs.

selection

Unrealistic or inferior


Conclusion


molecules with one good


property can go through the


Limitations

One million characters were sampled from the LSTM model, vielding 19.722 molecules, none of which were in the original training data.
















Molecules were evaluated based on five

PCA of Molecular Descriptors: Generated Molecules


visualized using PCA






<u>Advantages</u>

This cycle of de novo drug design provides scalable generation of molecules with multiobjective optimization.



After retraining the model with selected molecules, the molecules properties were visualized again.



Iterations

≥2